Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 426,138 shares of the biotechnology company's stock, valued at approximately $1,888,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.27% of Ironwood Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $36,000. Journey Strategic Wealth LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $47,000. Xponance Inc. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $50,000. Finally, Envestnet Asset Management Inc. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $50,000.

Ironwood Pharmaceuticals Stock Up 6.6%

IRWD stock traded up $0.04 during mid-day trading on Friday, hitting $0.61. 2,870,108 shares of the company were exchanged, compared to its average volume of 2,580,350. The firm has a market capitalization of $98.48 million, a P/E ratio of -20.29 and a beta of 0.37. The business has a fifty day simple moving average of $0.82 and a 200-day simple moving average of $2.18. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $7.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $41.14 million for the quarter, compared to analysts' expectations of $67.02 million. Research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on IRWD. Citizens Jmp cut shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Monday, April 14th. Wells Fargo & Company restated an "equal weight" rating and set a $1.00 price objective (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Jefferies Financial Group reaffirmed a "hold" rating and set a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Finally, Craig Hallum lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $4.78.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.